Larkin JMG, et al. 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma. Abstract LBA68_PR. ESMO Congress 2019, 28 sept, Barcelona, Spanje.
Iets meer lokale klachten bij radiotherapie na borstkankeroperatie
nov 2018 | Borstkanker, Radiotherapie